Track topics on Twitter Track topics that are important to you
Much-higher spending and one-time charges offset a12.6 percent jump in health care giant Johnson & Johnson's first-quarter revenue, trimming its profit by 1.2 percent, but the results still beat Wall Street expectations. The maker of baby products, medical devices and blockbuster immune disorder drug Remicade on Tuesday reported revenue of $20.01 billion, topping analyst projections for $19.48 billion.
Original Article: Johnson & Johnson tops 1Q views on sales spike, but net dipsNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...